Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04123366 · ClinicalTrials.gov registry record · Phase 2

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

A Phase 2 study of Solid Tumors, sponsored by Merck Sharp & Dohme.

Active
Registry status
Phase 2
Development phase
300
Enrollment target
20
Study locations

NCT04123366 is a Phase 2 study of Solid Tumors that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 300 participants, roughly in line with the 282-participant average among 125 other Solid Tumors trials with a reported enrollment target. The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04123366, a Phase 2 study of Solid Tumors, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
300 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to assess the efficacy and safety of treatment with olaparib (MK-7339) in combination with pembrolizumab (MK-3475) in adults with previously treated, advanced (metastatic and/or unresectable) Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-positive solid tumors.

Conditions Studied

Solid Tumors

Interventions

  • BIOLOGICAL Pembrolizumab
  • DRUG Olaparib

Study Locations (20)

California

  • UC Davis Comprehensive Cancer Center ( Site 0039) - Sacramento
  • San Francisco Oncology Associates ( Site 0085) - San Francisco
  • University of California San Francisco ( Site 0015) - San Francisco

Georgia

  • Winship Cancer Institute of Emory University ( Site 0057) - Atlanta
  • Northeast Georgia Medical Center ( Site 0026) - Gainesville
  • Northwest Georgia Oncology Centers PC ( Site 0047) - Marietta

Texas

  • Parkland Health & Hospital System ( Site 0091) - Dallas
  • University of Texas, Southwestern Medical Center ( Site 0004) - Dallas
  • University of Texas-MD Anderson Cancer Center ( Site 0087) - Houston

Alabama

  • The Kirklin Clinic ( Site 0086) - Birmingham

Arizona

  • Banner MD Anderson Cancer Center ( Site 0049) - Gilbert

Colorado

  • Banner MD Anderson Cancer Center ( Site 0092) - Greeley

Florida

  • University of Florida ( Site 0078) - Gainesville

Kentucky

  • Norton Cancer Institute - St. Matthews ( Site 0024) - Louisville

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2019-11-18
Est. Completion 2026-07-23
Phase Phase 2

Sponsor

Merck Sharp & Dohme

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04123366

The ClinicalTrials.gov registry entry for NCT04123366 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 282-participant average among 125 other Solid Tumors trials with a reported enrollment target. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT04123366 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Georgia, Texas.

Frequently Asked Questions

What is clinical trial NCT04123366 about?

NCT04123366 is a clinical study titled "Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)". The purpose of this study is to assess the efficacy and safety of treatment with olaparib (MK-7339) in combination with pembrolizumab (MK-3475) in adults with previously treated, advanced (metastatic and/or unresectable) Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination...

What is the current status of trial NCT04123366?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2019-11-18. Estimated completion is 2026-07-23.

What conditions does trial NCT04123366 study?

This clinical trial studies the following conditions: Solid Tumors.

What interventions are being tested in trial NCT04123366?

The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Olaparib (DRUG).

Who is sponsoring clinical trial NCT04123366?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04123366 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumors

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.